FEATURED ARTICLES

• Exploring MSC-EV Attributes – Analytical Comparison Of Tissue Sources And Production Platforms

  Uncover how analytical tools assess the impact of production process choices and tissue sources on the quality of cell-derived extracellular vesicles (EVs).

• Scalable GMP-Compatible Process Solution For MSC-EV Purification With 10X Yield Improvements

  Biological components in conditioned media are a consistent problem during downstream processing of EVs. A novel in-process reagent prevents these issues and improves particle recovery 10-fold while maintaining CQAs.

• A Scalable Manufacturing Platform For The Purification Of Stem Cell Derived Exosomes

  EV production scale increases require paired robust, scalable, and cost-effective downstream processes. Process parameters can be tailored for therapeutic exosome programs and allow for maximum exosome recovery.

• A Fed-Batch Chemically Defined hMSC-EV Bioprocess Medium Enabling 2-4x EV Yield Improvements In Bioreactor Culture

  A new chemically defined fed-batch bioprocess medium simplifies hMSC-EV production, increasing yields by 2-4x while maintaining EV quality across donors and tissue types in scalable GMP-compatible environments.

• Successful Development Of A Scalable And Robust Process For MSC-EV Production

  One of the challenges faced in EV production is scaling up manufacturing processes. Discover a reproducible and scalable microcarrier-based process for EV production in a stirred tank bioreactor system.

• Watch That Car-go! Acceleration Towards MSC-EV Characterization

  EV production must align with CMC and regulatory standards before it can reach its full potential. This study compares conditioned medium across scalable platforms to optimize EV manufacturing for the clinic.

• Top Five Downstream Processing Challenges For Viral Vectors And Exosomes

  From discovery to patient doses, viral vectors and exosomes face a complex journey. Researchers must navigate five key downstream processing challenges to ensure these therapies reach their full potential.

• Analytics: A Referee For The Tug-Of-War Between MSC-EVs' Nature And Nurture

  Like a referee in a contest, advanced analytical methods are essential to mediate the push and pull of different factors influencing therapeutic efficacy.

• AgentV's Virtues At The Vanguard Of Extracellular Vesicles

  Learn about a novel solution dramatically improving the purification and yield of promising nanoscale vesicles for medical applications.

• Logical Scale Out Before Scale Up

  Explore how synthetic biology and a "scale-out" biomanufacturing strategy can unlock "infinite diversity in infinite combinations," optimizing MSC functionality for superior outcomes.

• CD73: A Team Player Caught In The "AKT" Of Wound Healing And Cell Survival Via MSC Exosomes?

  CD73, found in MSC exosomes, is a key player in tissue repair. Discover how this protein contributes to cell survival and the intricate process of wound healing.

• A View From Experience In 3D Adherent Cell Culture For Advanced Therapies

  For efficient, scalable, and cost-effective cell and exosome production, 3D cell culture is the answer. Learn how this advanced approach surpasses 2D limitations, unlocking new potential for therapies.

• Double, Double, Experts Huddle, Cells And Bioprocess Bubble

  Biomanufacturing leaders unite to optimize exosome/EV production. Explore their combined upstream/downstream approach for optimized cell culture, purification, and quality control.

• The Immortal Question: Can MSCs Be "Like A Cell Line But Not A Cell Line?"

  Mesenchymal Stem Cells (MSCs) hold immense therapeutic promise. Can we harness their potential by making them more like consistent cell lines, without losing their unique advantages? Let's explore.

• EVs Answer To The CAR-Tease: Targeted Exosomes

  Researchers are exploring extracellular vesicles to deliver CARs, potentially offering safer, more accessible, and effective treatments compared to current CAR-T cell therapies.

• Simplifying EV/Exosome Research & Development

  Modern solutions are continuing to be developed to help those working in biologics overcome historic Exosomes / Extracellular Vesicles challenges.

• Build Support In The Early Days Of Advanced Therapy Entrepreneurship

  While more biotech companies are entering the market, advanced therapy startups can still benefit greatly from product and service options that help address challenges in the MSC or EV / exosome space.

• Time To Think Globally With Locally Acting Anti-Fibrotic Therapies

  Take a look at important information and data from PubMed publications regarding cancer and fibrosis research and as well as learning about MSCs & their EVs/Exosomes.

• On The Exosome/Extracellular Vesicle Frontier, Choose Your Own Adventure

  Gain insight into the importance of scalability for future clinical products made from extracellular vesicles, the quality of peer-reviewed extracellular vesicle/exosome science, and more.

• RoosterBio At ASGCT-2023: Confidently Crowing In A Crowd Of CRISPRs, Capsids, & CARs

  Explore the highlights of ASGCT-2023 and how RoosterBio uniquely contributed knowledge related to EVs and/or exosomes that benefitted those in attendance.